Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. TARS | 0.00 |
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:
TARS) with a Outperform and raises the price target from $97 to $100.